NCT01257048View on ClinicalTrials.gov

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
COPD Method EvaluationChronic Obstructive Pulmonary Disease Method Evaluation
Interventions
DRUG

Formoterol Turbuhaler

9 microgram on visit 5 single dose

DRUG

Budesonide/Formoterol Turbuhaler

320/9 microgram twice daily during 8 weeks

DRUG

Formoterol Turbuhaler

9 microgram twice daily during 8 weeks

Trial Locations (2)

Unknown

Research Site, Lund

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY